Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL973645 | 0.98 | LMNA (0.54) | LMNAKMT2AMAPTMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL28520522 | 0.98 | LMNA (0.54) | LMNAKMT2AMAPTMEN1NR1I2 | |
| Alcohol SCHEMBL11712776 | 0.97 | LMNA (0.53) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL2560081 | 0.91 | LMNA (0.62) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL7723352 | 0.91 | LMNA (0.51) | LMNAKMT2AMAPTMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL11625882 | 0.90 | LMNA (0.60) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL27603253 | 0.90 | LMNA (0.69) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL2467224 | 0.88 | LMNA (0.48) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL29111040 | 0.88 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL2565211 | 0.88 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-2383262-B1 | PHENYL PYRIMIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF | TOPHARMAN SHANGHAI CO LTD (CN) | 2016-07-06 | — | — | EP | disclosed |
| US-8871777-B2 | Phenylpyrimidone compounds, the pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| US-8871777-B2 | Phenylpyrimidone compounds, the pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| US-8871777-B2 | Phenylpyrimidone compounds, the pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-8178688-B2 | Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-05-15 | — | — | US | disclosed |
| EP-2383262-A1 | PHENYL PYRIMIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF | Topharman Shanghai Co., Ltd. (CN) | 2011-11-02 | — | — | EP | disclosed |
| US-5162316-A | Pyrimido[4,5-d]pyrimidine derivatives for use as bronchodilators | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-11-10 | — | — | US | disclosed |
| US-5118686-A | Administering bronchodilator agents for respiratory disorders | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-06-02 | — | — | US | disclosed |
| US-5047404-A | Fused pyrimidine derivatives bronchodilator agents, antiallergens | SMITH KLINE & FRENCH LABORATORIES, LTD. (GB) | 1991-09-10 | — | — | US | disclosed |
| EP-0400799-A1 | Phenylpyrimidone derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-12-05 | — | — | EP | disclosed |
| EP-0395328-A2 | Penylpyrimidone derivates and their use as therapeutic agents | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-10-31 | — | — | EP | disclosed |
| EP-0351058-A1 | Pyrimidopyrimidine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-01-17 | — | — | EP | disclosed |
| EP-0349239-A2 | Condensed pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
| EP-0347146-A2 | Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
| US-4082751-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4031093-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | LMNA 2421/4885KMT2A 3273/4885MAPT 2747/4885 |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | LMNA 3388/4885KMT2A 3125/4885MAPT 4683/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LMNA 1950/4885KMT2A 4179/4885MAPT 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.